All Fulcrum Publications

June 15, 2023

Development of the HealthMeasures Facioscapulohumeral Muscular Dystrophy-32 (HM FSHD-32) Patient-Reported Outcome Measure

Shaunfield S, K Kaiser, CN Hurt, GJ Greene, D Peipert, A Eldar-Lissai, D Cella

May 7, 2023

APPLYING MACHINE LEARNING (ML) TO ESTIMATE THE PREVALENCE OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) AND RELATED DISEASE BURDEN; FINDINGS FROM UNITED STATES CLAIMS ANALYSIS

Winnen A, S Srivatsa, A Eldar‐Lissai, I Kouchlev, G Jones, T Zuroske

April 22, 2023

Design of REACH: Phase 3 Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of the Efficacy and Safety of Losmapimod in FSHD

Tawil R, J Han, L Wang, J Vissing, J Statland, J Jiang

April 22, 2023

Muscle Ultrasound in an Open-Label Study of Losmapimod in Subjects with FSHD1

Kools J, N Voermans, K Mul, J Jiang, M Karlsson

March 19, 2023

Results from 96 Weeks of Dosing from the Open-Label Extension of a Phase 2 Trial of Losmapimod in Subjects with FSHD: ReDUX4

Wang L, J Han, J Jiang, R Tawil

October 11, 2022

Measuring Progression in FSHD: Implications for Clinical Trials

Shoskes J, L Wang, S Sacconi

August 1, 2022

Quantitative Muscle Analysis in FSHD Using Whole-Body Fat-Referenced MRI: Composite Scores for Longitudinal and Cross-sectional Analysis

Mellion ML, P Widholm, M Karlsson, A Ahlgren, R Tawil, KR Wagner, JM Statland, L Wang, PB Shieh, BGM van Engelen, J Kools, L Ronco, A Odueyungbo, J Jiang, JJ Han, M Hatch, J Towles, O Dahlqvist Leinhard, D Cadavid

August 1, 2022

Quantitative muscle analysis in facioscapulohumeral muscular dystrophy using whole-body fat-referenced MRI: Protocol development, multicenter feasibility, and repeatability

Quantitative muscle analysis in facioscapulohumeral muscular dystrophy using whole-body fat-referenced MRI: Protocol development, multicenter feasibility, and repeatability Widholm P, A Ahlgren, M Karlsson, T Romu, R Tawil, KR Wagner, JM Statland, LH Wang, PB Shieh, BGM van Engelen, D Cadavid, L Ronco, AO Odueyungbo, JG Jiang, ML Mellion, O Dahlqvist Leinhard Muscle Nerve 2022 Aug 66(2):183-192 doi: 10.1002/mus.27638 https://pubmed.ncbi.nlm.nih.gov/35585766/

June 10, 2022

Initial Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Data from an Ongoing Open-Label Study Investigating FTX-6058 in Adults Living with Sickle Cell Disease

Julie Kanter, Jae Ahn, Geoff Allen, Paul Bruno, Judy Dunn, Olga Mitelman, Chris Morabito, Billy Stuart, William Tracewell, John Ziegler

June 10, 2022

Inhibition of Polycomb Repressive Complex 2 Through EED Induces Fetal Hemoglobinin Healthy and Sickle Cell Disease Models

Billy Stuart, Paul Bruno, Damon Polioudakis, Mark Roth, Mary Wertz, Alexander Edelstein, Ivan Efremov, David Matson, Judy Dunn